Daniel Stephan Engeler

Daniel Stephan Engeler

Auto-generated profile, based on publicly available information

Daniel Stephan Engeler

Department of Urology, Kantonsspital St. Gallen, St. Gallen, Switzerland

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in European Urology
Verified
Journal Article
Closed access
MFMagnus Fall
Magnus Fall
ABAndrew P. Baranowski
Andrew P. Baranowski
SESohier Elneil
Sohier Elneil
DEDaniel Engeler
Daniel Engeler
JHJohn Hughes
John Hughes
AWAmanda Williams
Amanda Williams

19 June 2018 in BMJ
Verified
Journal Article
Open access
PDF file
DADominik Abt
Dominik Abt
LHLukas Hechelhammer
Lukas Hechelhammer
GMGautier Müllhaupt
Gautier Müllhaupt
SMStefan Markart
Stefan Markart
SGSabine Güsewell
Sabine Güsewell
LMLivio Mordasini
Livio Mordasini
Objective To compare prostatic artery embolisation (PAE) with transurethral resection of the prostate (TURP) in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia in terms of patient reported and functional outcomes. Design Randomised, open label, non-inferiority trial. Setting Urology and radiology departments of a Swiss tertiary care centre. Participants 103 patients aged ≥40 years with refractory lower urinary tract symptoms secondary to benign prostatic hyperplasia were randomised between 11 February 2014 and 24 May 2017; 48 and 51 patients reached the primary endpoint 12 weeks after PAE and TURP, respectively. Interventions PAE performed with 250-400 μm microspheres under local anaesthesia versus monopolar TURP performed under spinal or general anaesthesia. Main outcomes and measures Primary outcome was change in international prostate symptoms score (IPSS) from baseline to 12 weeks after surgery; a difference of less than 3 points between treatments was defined as non-inferiority for PAE and tested with a one sided t test. Secondary outcomes included further questionnaires, functional measures, magnetic resonance imaging findings, and adverse events; changes from baseline to 12 weeks were compared between treatments with two sided tests for superiority. Results Mean reduction in IPSS from baseline to 12 weeks was −9.23 points after PAE and −10.77 points after TURP. Although the difference was less than 3 points (1.54 points in favour of TURP (95% confidence interval −1.45 to 4.52)), non-inferiority of PAE could not be shown (P=0.17). None of the patient reported secondary outcomes differed significantly between treatments when tested for superiority; IPSS also did not differ significantly (P=0.31). At 12 weeks, PAE was less effective than TURP regarding changes in maximum rate of urinary flow (5.19 v 15.34 mL/s; difference 10.15 (95% confidence interval −14.67 to −5.63); P<0.001), postvoid residual urine (−86.36 v −199.98 mL; 113.62 (39.25 to 187.98); P=0.003), prostate volume (−12.17 v −30.27 mL; 18.11 (10.11 to 26.10); P<0.001), and desobstructive effectiveness according to pressure flow studies (56% v 93% shift towards less obstructive category; P=0.003). Fewer adverse events occurred after PAE than after TURP (36 v 70 events; P=0.003). Conclusions The improvement in lower urinary tract symptoms secondary to benign prostatic hyperplasia seen 12 weeks after PAE is close to that after TURP. PAE is associated with fewer complications than TURP but has disadvantages regarding functional outcomes, which should be considered when selecting patients. Further comparative study findings, including longer follow-up, should be evaluated before PAE can be considered as a routine treatment. Trial registration Clinicaltrials.gov NCT02054013.

1 December 2010 in European Urology
Verified
Journal Article
Closed access
Thomas M. KesslerThomas M. Kessler
Thomas M. Kessler
DFDavid La Framboise
David La Framboise
STSven Trelle
Sven Trelle
CFClare J. Fowler
Clare J. Fowler
GKGustav Kiss
Gustav Kiss
DEDaniel S. Engeler
Daniel S. Engeler

1 September 2013 in European Urology
Verified
Journal Article
Closed access
DEDaniel S. Engeler
Daniel S. Engeler
ABAndrew P. Baranowski
Andrew P. Baranowski
PDPaulo Dinis-Oliveira
Paulo Dinis-Oliveira
SESuzy Elneil
Suzy Elneil
JHJohn Hughes
John Hughes
AWAmanda Williams
Amanda Williams

1 March 2016 in JAMA Oncology
Verified
Journal Article
Closed access
PDF file
NJNicholas D. James
Nicholas D. James
MSMelissa R. Spears
Melissa R. Spears
NCNoel Clarke
Noel Clarke
DDDavid P. Dearnaley
David P. Dearnaley
MMMalcolm D. Mason
Malcolm D. Mason
FIfor the STAMPEDE Investigators
for the STAMPEDE Investigators
The STAMPEDE Trial (MRC PR08, CRUK/06/019) has recruited men starting first-line long-term hormone therapy (HT) for the first time for prostate cancer with or without metastases. The STAMPEDE population therefore includes a cohort of men with newly diagnosed nonmetastatic (M0) disease that is either high risk localized or node positive (N+); approximately 40% of trial entrants have no metastases. The trial uses a multiarm, multistage design to test the addition of further treatments to HT-based therapy, including docetaxel, zoledronic acid, celecoxib, abiraterone acetate, enzalutamide, and, only in patients with newly diagnosed metastatic (M1) disease, local radiotherapy (RT). Research arms have recruited at overlapping times, but, throughout, the control arm has consistently been use of HT, with RT where appropriate.1-8

1 November 2019 in European Urology Focus
Verified
Journal Article
Closed access
VZValentin Zumstein
Valentin Zumstein
PBPatrick Betschart
Patrick Betschart
MVMalte W. Vetterlein
Malte W. Vetterlein
LKLuis A. Kluth
Luis A. Kluth
LHLukas Hechelhammer
Lukas Hechelhammer
DADominik Abt
Dominik Abt